Likewise, OCT3 expression is seen in renal carcinoma cell lines and its expression has been linked to increased sensitivity to cytostatic drugs suggesting that the presence of OCT3 may be used to tailor therapies [77]. Here, SLC22A3 is linked to renal carcinoma.